LH (Labcorp Holdings) 10-Year RORE % : 3.95% (As of Mar. 2026)


LH Labcorp Holdings Inc LH
80 GF Score
Price $276.81
GF Value $272.14
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Labcorp Holdings 10-Year RORE %?

Labcorp Holdings LH -0.30% 80 10-Year RORE % is 3.95 as of Mar. 2026. GuruFocus rates LH with a GF Score™ of 80/100 and a GF Value™ of $272.14 (Fairly Valued). The stock has 6 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, Labcorp Holdings ranks better than 55.37% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Labcorp Holdings's 10-Year RORE % for the quarter that ended in Mar. 2026 was 3.95%.

The industry rank for Labcorp Holdings's 10-Year RORE % or its related term are showing as below:

LH's 10-Year RORE % is ranked better than
55.37% of 121 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.55 vs LH: 3.95

Labcorp Holdings  (NYSE:LH) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Labcorp Holdings 10-Year RORE % Related Terms


Labcorp Holdings 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Labcorp Holdings's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labcorp Holdings 10-Year RORE % Chart

Labcorp Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.66 7.30 -1.28 4.52 3.35

Labcorp Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.76 2.85 3.71 3.35 3.95

LH vs DGX, GH, MTD: 10-Year RORE % Comparison

For the Diagnostics & Research subindustry, Labcorp Holdings's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labcorp Holdings 10-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Labcorp Holdings's 10-Year RORE % falls into.


LH
80GF Score
Labcorp Holdings Inc LH
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labcorp Holdings 10-Year RORE % Calculation

Labcorp Holdings's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 11.29-7.17 )/( 115.7-11.52 )
=4.12/104.18
=3.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 3.95 mean?
Labcorp Holdings (LH) has a 10-Year RORE % of 3.95 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Labcorp Holdings and its competitors. According to the industry distribution chart, Labcorp Holdings ranks #54 out of 121 companies in the Medical Diagnostics & Research industry, placing it in the top 44.6%.
Is Labcorp Holdings' 10-Year RORE % too high?
Labcorp Holdings' current 10-Year RORE % is 3.95. The Medical Diagnostics & Research industry median 10-Year RORE % is 1.55. Labcorp Holdings' value of 3.95 is 154.8% above this industry median. Based on the distribution chart, Labcorp Holdings ranks #54 out of 121 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Labcorp Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' 10-Year RORE % compare to DGX and GH?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #54 out of 121 companies for 10-Year RORE %. This puts Labcorp Holdings in the upper half of its industry. The industry median 10-Year RORE % is 1.55. Labcorp Holdings' value of 3.95 is 154.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
The median 10-Year RORE % among Medical Diagnostics & Research companies is 1.55, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current 10-Year RORE % of 3.95 is 154.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year RORE % is 1.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current 10-Year RORE % is 3.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LH) is currently considered Fairly Valued. The stock's GF Value™ is $272.14, compared to a current price of $276.81 — trading 1.7% above its estimated fair value. The current 10-Year RORE % is 3.95 and 154.8% above the Medical Diagnostics & Research industry median of 1.55. Labcorp Holdings' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Labcorp Holdings (LH), the current 10-Year RORE % is 3.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labcorp Holdings (LH) Overvalued in 2026?

Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued. The current stock price of $276.81 is trading 1.7% above its estimated GF Value™ of $272.14. GuruFocus considers Labcorp Holdings to be Fairly Valued.

Key valuation signals for LH:

  • 10-Year RORE %: 3.95
  • GF Value™: $272.14 vs. price of $276.81 (1.7% above fair value)
  • GF Score™: 80/100 with 6 warning signs
  • Industry Position: 154.8% above the Medical Diagnostics & Research median (#54 of 121)

No single metric tells the full story. See the LH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Labcorp Holdings Business Description

Other Exchanges 0JSY:UKN6B:Germany
Address 358 South Main Street, Burlington, NC, USA, 27215
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
80GF Score

Get the complete analysis for LH

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$276.81
Price
$272.14
GF Value